Abstract: The present invention includes novel systems, methods, and compositions for the enzymatic/chemical production of pseudouridine (?) and its variants, such as N1-methyl-pseudouridine-5?-triphosphate (m1?TP).

Abstract: The invention includes a novel microfluidic mixing chip configured for the production of lipid nano-particles (LNPs) and in particular LNPs encapsulating oligonucleotides, such as mRNA that may be used in various therapeutic applications such as vaccines and the like.

Abstract: The present invention includes novel systems, methods, and compositions for the enzymatic/chemical production of pseudouridine (?) and its variants, such as N1-methyl-pseudouridine-5?-triphosphate (m1?TP).

Abstract: The present invention includes novel systems, methods, and compositions for the enzymatic/chemical production of pseudouridine (?) and its variants, such as N1-methyl-pseudouridine-5?-triphosphate (m1?TP).

Abstract: The invention includes novel, systems, methods and compositions for the in vitro production of polynucleotides, and in particular the production of mRNA for use in therapeutic applications.

Abstract: The inventive technology includes a novel immunostimulatory RNA vaccine for the COVID-19 coronavirus. In one preferred aspect, the inventive technology includes a novel mRNA sequence encoding at least one antigenic peptide or protein comprising or consisting of a COVID-19 coronavirus protein or a fragment or variant thereof.

Abstract: Another aim of the current invention may include a recombinant cell-free expression system, the reaction mixture containing all the cell-free reaction components necessary for the in vitro biosynthesis of biological compounds, proteins, enzymes, biosimilars or chemical modification of small molecules.

Abstract: The invention relates to an in vitro cell-free expression system incorporating a novel inorganic polyphosphate-based energy regeneration system. In certain embodiments, the invention includes a cell-free expression system where the cellular energy source, ATP, is regenerated from inorganic polyphosphate using a dual enzyme system. In this embodiment, this dual enzyme system may include thermostable Adenosyl Kinase, and/or Polyphosphate Kinase enzymes.

Abstract: The invention relates to an in vitro cell-free expression system incorporating a novel inorganic polyphosphate-based energy regeneration system. In certain embodiments, the invention includes a cell-free expression system where the cellular energy source, ATP, is regenerated from inorganic polyphosphate using a dual enzyme system. In this embodiment, this dual enzyme system may include thermostable Adenosyl Kinase, and/or Polyphosphate Kinase enzymes.

Abstract: The invention relates to an in vitro cell-free expression system incorporating a novel inorganic polyphosphate-based energy regeneration system. In certain embodiments, the invention includes a cell-free expression system where the cellular energy source, ATP, is regenerated from inorganic polyphosphate using a dual enzyme system. In this embodiment, this dual enzyme system may include thermostable Adenosyl Kinase, and/or Polyphosphate Kinase enzymes.

Abstract: The discovery of a non-ribosomal peptide synthetase (NRPS) gene cluster in the genome of Clostridium thermocellum that produces a secondary metabolite that is assembled outside of the host membrane is described. Also described is the identification of homologous NRPS gene clusters from several additional microorganisms. The secondary metabolites produced by the NRPS gene clusters exhibit broad spectrum antibiotic activity. Thus, antibiotic compounds produced by the NRPS gene clusters, and analogs thereof, their use for inhibiting bacterial growth, and methods of making the antibiotic compounds are described.

Abstract: The discovery of a non-ribosomal peptide synthetase (NRPS) gene cluster in the genome of Clostridium thermocellum that produces a secondary metabolite that is assembled outside of the host membrane is described. Also described is the identification of homologous NRPS gene clusters from several additional microorganisms. The secondary metabolites produced by the NRPS gene clusters exhibit broad spectrum antibiotic activity. Thus, antibiotic compounds produced by the NRPS gene clusters, and analogs thereof, their use for inhibiting bacterial growth, and methods of making the antibiotic compounds are described.

Abstract: A compound, or a pharmaceutically acceptable salt, ester, hydrate or solvate thereof, comprising formula IV: A-B wherein A comprises a substrate for an enzyme of a microorganism; B comprises an odorant moiety; B is covalently bonded to an anomeric carbon of A; and A is enzymatically cleavable from B at the covalent bond site between A and B by the enzyme of the microorganism. Examples of such compounds are referred to as substrate-odorant compounds or odorant chimeras. Also disclosed are methods for detecting a microorganism that include contacting the compound with a sample that may include the microorganism.